All In Biotech

Drug Trial Radar · NCT06630234

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

155

Planned (sponsor's estimate)

Start

Dec 10, 2024

Primary completion

May 2028

Study completion May 2028

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Oct 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 3 parts: Part 1 (Dose Escalation), Part 2 (Dose Expansion), and Part 3 (Food Effect \[FE\] and Drug-Drug Interaction \[DDI\]). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.

Conditions

  • Gastrointestinal Stromal Tumor (GIST)

Interventions

  • DCC-3009Drug

    Administered orally

  • RabeprazoleDrug

    Administered orally (Part 3 only)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose-Limiting Toxicities (DLT) (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
  2. Number of Participants with Treatment-emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
  3. Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
  4. Objective Response Rate (ORR) (Part 2 Expansion)Time frame: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
  5. Pharmacokinetics (PK): Time to Maximum Observed Plasma Concentration (Tmax) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
  6. PK: Maximum Observed Plasma Drug Concentration (Cmax) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
  7. PK: Trough Plasma Concentration (Ctrough) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
  8. PK: Area Under the Plasma Concentration-time Curve (AUC) (Part 3 FE and DDI)Time frame: Estimated up to 24 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdate, Arizona · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Vanderbilt University-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.